Selskabets formål er at udvikle, markedsføre og sælge lægemidler samt al virksomhed, som efter direktionens skøn er beslægtet hermed
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 3.7 mio. | 707 t. | 1.9 mio. | 1.7 mio. | - | |
CVR: 40868151
Compared to 129 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Farzad Abdi-Dezfuli left the board
Jonas Hallén left the board
Susanne Stuffers left the board
Jonas Hallén joined as director
Berte Aagot Hedding Poulsson joined as director
Susanne Stuffers left as director
ARXX Therapeutics ApS has demonstrated a positive trajectory in financial health, with revenue increasing from 2.6 million DKK in 2024 to 3.7 million DKK in 2025, alongside a significant rise in profit from 116,729 DKK to 706,595 DKK. The company has shown resilience despite a dip in revenue in 2023 compared to 2022, indicating potential volatility in sales. Notably, equity has improved markedly from 177,355 DKK in 2021 to 1,688,804 DKK in 2025, reflecting a strengthening balance sheet. However, the fluctuating revenue and profit margins suggest a need for strategic stability as the company navigates the competitive pharmaceutical manufacturing industry.
AI-generated summary
Companies in the same industry and area
companydata.dk